Ticagrelor in Severe Community Acquired Pneumonia

PHASE2TerminatedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
Community Acquired Pneumonia, Severe
Interventions
DRUG

Ticagrelor

Ticagrelor 180 mg loading dose followed by 90 mg BID for 90 days

DRUG

Placebo

Placebo 180 mg loading dose followed by 90 mg BID for 90 days.

Trial Locations (26)

21201

University of Maryland Medical Center, Baltimore

22908

University of Virginia, Charlottesville

27401

Moses Cone, Greensboro

30033

Atlanta VA Medical Center, Atlanta

37232

Vanderbilt University Medical Center, Nashville

40536

University of Kentucky, Lexington

43210

The Ohio State University, Columbus

44195

Cleveland Clinic, Cleveland

53226

Medical College of Wisconsin, Milwaukee

55101

Regions Hospital, Saint Paul

60611

Northwestern University, Chicago

76508

Scott & White Memorial Hospital, Temple

77030

Baylor, Houston

Memorial Hermann Hospital - Texas Medical Center, Houston

78229

South Texas Veterans Health Care System, San Antonio

University of Texas Health Science Center San Antonio, San Antonio

80204

Denver Health, Denver

80909

University of Colorado, Colorado Springs

84107

Intermountain Medical Center, Murray

84108

University of Utah, Salt Lake City

85724

University of Arizona, Tucson

97210

Legacy Good Samaritan Medical Center, Portland

97227

Legacy Emanuel Medical Center, Portland

97239

Oregon Health Sciences University, Portland

01199

Baystate Medical Center, Springfield

02903

Rhode Island Hospital, Providence

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Gordon Bernard

OTHER